Guaiacol

Guaiacol

SCHEMBL21542

COc1ccccc1O.O=C(O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Guaiacol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.82
CA2 P00918 3/20 0.82
TP53 P04637 2/20 0.82
TSHR P16473 2/20 0.82
MAPT P10636 4/20 0.58
KDM4E B2RXH2 3/20 0.58
LMNA P02545 3/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPK1 P28482 2/20 0.58
CYP3A4 P08684 2/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 2/20 0.58
ALOX15 P16050 1/20 0.58
ALOX12 P18054 1/20 0.58
CA12 O43570 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
CA4 P22748 1/20 0.52
HTT P42858 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guaiacol SCHEMBL5665553 0.93 CA1 (0.78) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL11574553 0.93 CA1 (0.95) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL27937887 0.93 CA1 (0.95) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL5176489 0.92 CA1 (0.69) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL10856965 0.91 CA1 (0.75) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL28032481 0.91 CA1 (0.82) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL671733 0.91 CA2 (1.00) CA1CA2TP53TSHRMAPT
Guaiacol SCHEMBL29454477 0.91
Guaiacol SCHEMBL21626 0.91
Guaiacol SCHEMBL7134809 0.88 CA1 (0.86) CA1CA2TP53TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024846-A Method for degrading polycarbonate by using phenol catalyst 中国科学院青岛生物能源与过程研究所 2023-11-10 CN claimed
CN-109988296-B Process for producing polycarbonate polyol and polycarbonate polyol composition 财团法人工业技术研究院 2021-09-10 CN claimed
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 WO claimed
US-10689488-B2 Method for preparing polycarbonate polyol and composition comprising the polycarbonate polyol INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2020-06-23 US claimed
CN-111138406-A Sulfonium sulfonate photo-acid generator synthesized from guaiol and synthesis method thereof 上海博栋化学科技有限公司 2020-05-12 CN claimed
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2020-02-13 US claimed
US-20190202981-A1 METHOD FOR PREPARING POLYCARBONATE POLYOL AND COMPOSITION COMPRISING THE POLYCARBONATE POLYOL INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2019-07-04 US claimed
US-9622969-B2 Polymer conjugated protein micelles SOUTH DAKOTA STATE UNIV (US) 2017-04-18 US claimed
US-20140370110-A1 POLYMER CONJUGATED PROTEIN MICELLES SOUTH DAKOTA STATE UNIVERSITY (US) 2014-12-18 US claimed
EP-2729136-A1 DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION Biocopea Limited (GB) 2014-05-14 EP claimed
CN-103648488-A Pharmaceutical compositions and use in treating cough conditions BIOCOPEA LTD 2014-03-19 CN claimed
EP-2608847-A1 THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY Biocopea Limited (GB) 2013-07-03 EP claimed
WO-2013004999-A1 DRUG COMBINATIONS AND USES IN TREATING A COUGHING CONDITION BIOCOPEA LIMITED (GB) 2013-01-10 WO claimed
WO-2012025761-A1 THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY BIOCOPEA LIMITED (GB) 2012-03-01 WO claimed
EP-4519340-B1 PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING COVESTRO DEUTSCHLAND AG (DE) 2026-04-01 EP disclosed
EP-4022391-B1 HEAT SENSITIVE RECORDING MATERIAL WITH NON-PHENOLIC COLOR DEVELOPERS SOLENIS TECHNOLOGIES CAYMAN LP (KY) 2026-03-04 EP disclosed
EP-4463503-B1 PROCESS FOR PREPARING POLYCARBONATE BY BLANC-TYPE METHYLATION COVESTRO DEUTSCHLAND AG (DE) 2025-12-24 EP disclosed
US-5306687-A Optical recording media comprising p'-methylphenyl p-chlorobenzoate as thermosensitizers RICOH COMPANY, LTD. (JP) 1994-04-26 US disclosed
EP-0055313-A1 Guaiacol and derivatives; compositions thereof and use in a method of treatment ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE (CH) 1982-07-07 EP disclosed
US-938132-A GUAIACOL CARBONATE SULFO-ACID DERIVATIVE. BOEHRINGER SOHN INGELHEIM (DE) 1909-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS GSTK1, GSTO1, GSTM2 CA1 725/4885CA2 2428/4885TP53 4095/4885
US-20140370110-A1 POLYMER CONJUGATED PROTEIN MICELLES MTDH, PSMG3, GHITM CA1 3087/4885CA2 4462/4885TP53 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.